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permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.SUMMARYMesenchymal stromal cells (MSCs) are multilineage progenitors with immunomodulatory properties, including expansion of immuno-
modulatory leukocytes such as regulatory T lymphocytes (Tregs) and tolerogenic dendritic cells.We report that humanMSCs can expand
CD14CD11b+CD33+ human myeloid-derived suppressor cells (MDSCs). MSC-expanded MDSCs suppress allogeneic lymphocyte
proliferation, express arginase-1 and inducible nitric oxide synthase, and increase the number of Tregs. This expansion occurs through
the secretion of hepatocyte growth factor (HGF), with effects replicated by adding HGF singly and abrogated by HGF knockdown in
MSCs. In wild-type mice, the liver, which secretes high levels of HGF, contains high numbers of Gr-1+CD11b+ MDSCs, and injection
of HGF into mice significantly increases the number of MDSCs. Expansion of MDSCs by MSC-secreted HGF involves c-Met (its receptor)
and downstream phosphorylation of STAT3, a key factor in MDSC expansion. Our data further support the strong immunomodulatory
nature of MSCs and demonstrate the role of HGF, a mitogenic molecule, in the expansion of MDSCs.INTRODUCTION
Multipotent mesenchymal stromal cells (MSCs) are a pop-
ulation of multilineage progenitor cells that were first iso-
lated from the bone marrow (Friedenstein, 1976; Pittenger
et al., 1999). These somatic progenitor cells harbor the
capacity to differentiate into adipocytes, osteoblasts, and
chondrocytes, as well as a number of extramesodermal
lineages (Prockop, 1997). Recent studies have demon-
strated that MSCs exert strong immunomodulatory effects
on multiple populations of leukocytes via various mecha-
nisms, including suppression of CD4 and CD8 lymphocyte
proliferation and responses, induction of T regulatory
lymphocytes (Tregs; a population of immunomodulatory
T cells), and secretion of immunosuppressive molecules
such as transforming growth factor-b (TGF-b) and indole-
amine-2,3-dioxygenase (IDO) (Uccelli et al., 2008). MSCs
also strongly suppress natural killer lymphocyte cytotox-
icity and affect dendritic cell (DC) maturation, e.g., by
inhibiting the differentiation of monocytes to immature
myeloid DCs and decreasing the effector functions ofStem Cplasmacytoid DCs (Le Blanc and Mougiakakos, 2012;
Uccelli et al., 2008). Many of these components are
similar to the immunomodulatory armamentarium of the
immune system, which is important for preventing auto-
immunity and establishing tolerance (Guleria and Sayegh,
2007; Wing and Sakaguchi, 2010), with mechanisms
ranging from anti-inflammatory molecules such as TGF-b,
IDO, and interleukin-10 (IL-10) to leukocyte subpopula-
tions such as Tregs and tolerogenic DCs (Mellor and
Munn, 2004; Sakaguchi et al., 2006; Swiecki and Colonna,
2010).
As with many biological phenomena, immunomodula-
tion is a double-edged sword, and many of these tolero-
genic mechanisms appear to be manipulated by cancer
cells to create an immunoprivileged niche to further their
own growth (Rabinovich et al., 2007). One of the most
prominent immunomodulatory leukocyte subpopulations
in cancer consists of myeloid-derived suppressor cells
(MDSCs) (Ostrand-Rosenberg and Sinha, 2009). Derived
from myeloid precursors, MDSCs suppress immune
response by a number of mechanisms, such as suppressingell Reports j Vol. 1 j 139–151 j August 6, 2013 j ª2013 The Authors 139
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T cells by expressing the enzymes arginase 1 (ARG1) and
inducible nitric oxide synthase (iNOS), both ofwhich block
the production of the T cell CD3-z chain by metabolizing
L-arginine (Gabrilovich and Nagaraj, 2009; Gabrilovich
et al., 2012). Human and mouse studies have revealed
that chronic inflammation and proinflammatory media-
tors such granulocyte macrophage colony-stimulating
factor (GM-CSF), IL-1b, IL-6, and prostaglandin E2 (PGE2)
are involved in the induction of these suppressor leuko-
cytes (Bunt et al., 2007; Serafini et al., 2004; Sinha et al.,
2007; Young and Wright, 1992). Although it is clear that
the tumor microenvironment is maintained by diverse
cell types, the role of secreted factors other than cytokines
and proinflammatory factors in the expansion of MDSCs
has largely been unexplored, with the exception of vascular
endothelial growth factor (Fricke et al., 2007; Shojaei et al.,
2007). We report that MDSCs can be expanded by MSC-
secreted hepatocyte growth factor (HGF), a potent mito-
genic growth factor.RESULTS
MSCs Can Expand High Numbers of Functional
CD14CD11b+CD33+ MDSCs from Peripheral Blood
Leukocytes
We hypothesized that the strong immunosuppressive
properties of diverse sources of MSCs extend to involve
the expansion of MDSCs. We first isolated and cultured
MSCs from placenta and bonemarrow, and then character-
ized the cells for surface marker expression and multi-
lineage differentiation potential. Both bone marrow and
placental MSCs are positive for surface expression of
CD73, CD105, and CD90, but negative for hematopoietic
markers such as the costimulatory molecules CD80 and
86 (Figure 1A; Chang et al., 2006; Uccelli et al., 2008; Yen
et al., 2005). Both populations of MSCs can differentiate
into osteoblastic, chondrogenic, and adipocytic lineages,
and thusmeet the criteria formultipotentMSCs (Figure 1B;
Dominici et al., 2006; Liu et al., 2011; Pittenger et al., 1999).
To test whetherMSCs can expandMDSCs, we cocultured
MSCs with human peripheral blood leukocytes (PBLs) and
assayed for MDSCs, which in the human system are most
commonly characterized as CD14CD11b+CD33+ leuko-
cytes with a strong suppressor function (Ostrand-Rosen-
berg and Sinha, 2009; Poschke and Kiessling, 2012). We
found that both bone marrow and placental MSCs could
increase the number of CD14CD11b+CD33+ cells from
PBLs (Figure 2A). Both cell percentage and numbers were
increased significantly after PBL coculture with MSCs,
with CD11b+ cells showing an increase from a baseline of
8.9% ± 0.6% (10,179 ± 926 cells; averages ± SEM) to140 Stem Cell Reports j Vol. 1 j 139–151 j August 6, 2013 j ª2013 The Auth19.2% ± 1.2% (19,508 ± 1,258 cells) after coculture with
MSCs, and CD14CD11b+CD33+ cells increasing from
1.3% ± 0.1% (1,052 ± 90 cells) at baseline to 2.4% ± 0.2%
(2,343 ± 147 cells) after coculture with MSCs (Figure 2B).
To assess whether these MSC-expanded MDSCs were func-
tional, we sorted MSC-induced CD14CD11b+CD33+ cells
and cocultured these cells with allogeneic proliferating
lymphocytes to assess for suppressive capacity. We found
that the MSC-expanded CD14CD11b+CD33+ cells could
suppress lymphocyte proliferation in a dose-dependent
manner (Figure 2C). Human MDSCs are known to express
ARG1 and iNOS (Ochoa et al., 2007; Rodrı´guez and Ochoa,
2008), and we found that MSC-induced MDSCs also ex-
pressed these enzymes and at significantly higher cell
numbers compared with baseline (Figures 2D and 2E,
respectively). MDSCs have also been shown to express
IL-10 and TGFb in some reports (Poschke and Kiessling,
2012), but we did not find any expression of these mole-
cules at baseline or after MSC coculture (Figure S1A
available online). CD14CD11b+CD33+ MDSCs have
been reported to induce Tregs (Dugast et al., 2008; Huang
et al., 2006), and we also found that MSC-induced
CD14CD11b+CD33+ cells were able to induce high
numbers of CD4+CD25highCD127low Tregs from stimulated
PBL (Figures 2F and S1B). Thus, MSC-expanded
CD14CD11b+CD33+ cells have multiple immunomodu-
latory functions.
Expansion of MDSCs by MSCs Is Mediated by
Secreted HGF
We next investigated the mechanisms involved in MSC
expansion of MDSCs. We found that the expansion of
MDSCs by MSCs was not affected by transwell separation
of cells, indicatig that cell-cell contact was not needed
and implicating secreted factors in this process (Figure 3A).
We therefore analyzed the conditionedmediumofMSCs to
assess for relevant secreted molecules. MSCs secrete a
number of stromal-related factors, such as RANTES/CCL5,
HGF, and IL-6, the latter of which has been implicated in
the expansion of MDSCs (Bunt et al., 2007; Figure 3B).
However, using both blocking antibodies and small
interfering RNA (siRNA) knockdown studies, we did not
find that IL-6 contributed to the expansion of MDSCs by
MSCs (Figure S2).
It was previously reported that STAT3 is critical for the
expansion of MDSCs (Gabrilovich and Nagaraj, 2009).
STAT3 is also an importantmolecule in the signal transduc-
tion pathway of HGF (Trusolino et al., 2010), a molecule
that is known to be highly secreted by many cell types,
including MSCs (Di Nicola et al., 2002; Takai et al., 1997;
Trusolino et al., 2010). Since we also found that HGF was
highly secreted by MSCs (Figure 3B), we assessed whether
this molecule is involved in MSC expansion of MDSCs.ors
Figure 1. Characterization of Bone
Marrow and Placental Multipotent MSCs
(A and B) Surface marker profile (A) and
trilineage differentiation phenotype (B) for
bone marrow (BM) multipotent MSCs and
placental MSCs (P-MSCs). Adipo, adipogenic
lineage (stained with oil red O to assess for
oil droplet formation); chondro, chondro-
genic lineage (stained with Alcian blue to
assess for the presence of glucosaminogly-
cans); osteo, osteogenic lineage (stained
with alizarin red to assess calcium deposi-
tion). Scale bar: 200 mm.
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MSC-Secreted HGF Expand MDSCs via c-Met and STAT3We found that the addition of recombinant HGF alone
could result in the expansion of MDSCs, and this effect
was dose dependent up to a concentration of 30 ng/ml (Fig-
ure 3C), which is approximately the upper limit found in
MSC-conditioned medium (Figure 3B). HGF-expanded
MDSCs also expressed iNOS and ARG1, and at higher cellStem Cnumbers compared with baseline (Figure 3D). Moreover,
HGF-expanded MDSCs can suppress allogeneic lympho-
cytes proliferation as well (Figure 3E). To further ascertain
the involvement of HGF in MSC expansion of MDSCs,
we suppressed the secretion of HGF by MSCs with siRNA.
Using siRNA specific for HGF, we were able to effectivelyell Reports j Vol. 1 j 139–151 j August 6, 2013 j ª2013 The Authors 141
Figure 2. Human MSCs Expand the Number of Functional CD14CD11b+CD33+ MDSCs in Allogeneic PBLs
(A) Expansion of CD14CD11b+CD33+ cells from PBLs by MSCs. Allogeneic PBLs (40 donors) were cocultured alone (top panel) or with MSCs
(lower panel; three donors of BM-MSCs and four donors of P-MSCs; representative dot plots/ histogram shown). PBLs were gated on forward
(legend continued on next page)
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MSC-Secreted HGF Expand MDSCs via c-Met and STAT3suppress the secretion of the molecule by MSCs, and this
abrogated the expansion of MDSCs by MSCs (Figure 3F).
Thus, our data support that HGF secreted by MSCs is
involved in the expansion of MDSCs.
HGF is a well-known and important mitogen for cancer
cell growth (Mueller and Fusenig, 2004). Because MDSCs
play a critical role in creating the immunoprivileged niche
of tumors, we assessedwhether cancer cell lines that secrete
high levels of HGF could expand higher numbers of
MDSCs. We found that, indeed, the level of HGF secreted
by several cell lines correlated with the number of MDSCs
expanded (Figures 4A and 4B). We then assessed the role
of MSC-secreted HGF in the in vivo setting of the tumor
microenvironment. When mice were inoculated with tu-
mor cells admixed with MSCs silenced for HGF expression,
there was a significant reduction in tumor-associated
Gr-1+CD11b+ MDSCs (Figure 4C). Moreover, in both
wild-type C57BL/6 and BALB/c mice, we found that the
liver, an organ that is known to secrete high levels of
HGF, contained a significantly higher proportion of
Gr-1+CD11b+ MDSCs than the spleen (Figure 4D). Further-
more, when we inhibited the HGF/c-Met pathway in wild-
type mice by injecting PHA-665752 (a second-generation
c-Met inhibitor; Christensen et al., 2003), we observed a
significant decrease in hepatic, but not splenic, MDSCs,
even after we excluded other myeloid cells, such as macro-
phages and Kupffer cells (resident hepatic macrophages),
using the surface marker F4/80 (Kinoshita et al., 2010;
Lee et al., 1986; Figures 4E and S3). Critically, the HGF/
c-Met pathway appears to be responsible for the high
numbers and vast majority of hepatic Gr-1+CD11b+F4/
80MDSCs, since c-Met inhibition resulted in a significantscatter (FSC)/side scatter (SSC) (R1, 100,000 events for all analyses
CD33+ (R3).
(B) Quantification of percentage (left-side charts) and cell number (rig
MDSCs (lower graphs) before and after coculture with MSCs. Averages
PBL only.
(C) Suppressive function of MSC-induced MDSCs. Allogeneic PBLs (T, t
cell division and stimulated with anti-CD3/28 (a-CD3/28) without or
various E:T ratios. Flow-cytometric analysis was performed to asses
staining. The chart on the right is a quantitative summary of experime
y axis: percentage suppression of PBL proliferation by MSC-expand
E, effector cells.
(D and E) Expression of iNOS (D) and ARG1 (E) by MSC-expanded MDSCs
selected CD14 cells from PBLs (eight donors) were cultured alone (top
SSC (R1), analyzed for CD11b+ and CD33+ (R2), and further analyzed
unfilled black line: isotype control). Average cell numbers ± SEM ar
comparing CD14 + MSCs with CD14 only.
(F) Expansion of CD4+CD25high Tregs by MSC-expanded MDSCs. CD14C
and cocultured with anti-CD3/28-stimulated allogeneic PBLs (three d
T cells. The chart on the right is a quantitative summary of the experim
with anti-CD3/28-activated PBL (leftmost bar).
See also Figure S1.
Stem Closs of70% of this population (Figure 4E), which was not
observed for splenic MDSCs. These results are highly sug-
gestive of a critical role for HGF in maintaining the high
numbers of MDSCs in the liver. To further validate the
in vivo relevance of our findings, we injected recombinant
HGF intravenously into wild-type C57BL/6 mice. After
3 days, we found a significant increase of Gr-1+CD11b+
MDSCs in the bone marrow (where myeloid cells are
most abundant; Gabrilovich et al., 2012) of thesemice (Fig-
ure 4F), indicating that HGF can expand MDSCs in an
in vivo setting. Collectively, these results indicate the rele-
vance of HGF in tumor-associated MDSCs and in vivo
settings.
Expansion of MDSCs by HGF Is Mediated by the HGF
Receptor c-Met and Increased Phosphorylation of
STAT3
To investigate the mechanism behind HGF-mediated
expansion of MDSCs, we checked for expression of c-Met,
the cognate receptor for HGF (Cecchi et al., 2010; Trusolino
et al., 2010), on MDSCs. We found that CD14 leukocytes
and MDSCs constitutively expressed low levels of c-Met
(Figures 5A and S4), and when c-Met on PBLs was blocked
with neutralizing antibodies, the expansion of MDSCs by
HGF was abrogated (Figure 5B). To investigate whether
the effects of the HGF/c-Met axis were mediated through
STAT3, we checked for HGF-induced STAT3 phosphoryla-
tion, which indicates activation of the pathway, inMDSCs.
We found that exogenous addition of HGF induced an
increase over baseline levels of phosphorylated STAT3
(pSTAT3), most consistently and significantly at 1 hr after
treatment (Figures 5C and S5). Moreover, when the), analyzed for CD14 and CD11b+ (R2), and further analyzed for
ht-side charts) of PBL CD11b+ (upper graphs) or CD14CD11b+CD33+
± SEM; 57 independent experiments; ***p < 0.001 compared with
arget cells; eight donors) were stained with CFSE for assessment of
with the addition of MSC-expanded MDSCs (from three donors) at
s PBL cell proliferation/division as evidenced by decreasing CFSE
ntal results; x axis: ratio of MSC-expanded MDSCs to activated PBL;
ed MDSCs; eight independent experiments; *p < 0.05 for trend.
(five donors of MSCs; representative histograms shown). Negatively
panels) or with MSCs (lower panels). CD14 cells were gated on FSC/
for either (D) iNOS or (E) ARG1 (shaded gray areas in histogram;
e indicated in the upper-right corner of the histogram; *p < 0.05
D11b+CD33+ MSC-expanded MDSCs (three donors) were FACS sorted
onors) at various ratios and assessed for induction of CD4+CD25high
ental results of three independent experiments. *p < 0.05 compared
ell Reports j Vol. 1 j 139–151 j August 6, 2013 j ª2013 The Authors 143
(legend on next page)
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MSC-Secreted HGF Expand MDSCs via c-Met and STAT3STAT3 inhibitor cpd188 was added in the presence of exog-
enous HGF, the expansion of MDSCs was abrogated in a
dose-dependent fashion (Figure 5D). Thus, HGF mediates
the expansion of MDSCs by binding to its receptor,
c-Met, which leads to increased phosphorylation of
STAT3 (Fig. 6).DISCUSSION
Recent reports have highlighted MDSCs as a prominent
leukocyte subpopulation involved not only in tumor-asso-
ciated immune suppression but also in regulation of the
immune system at large (Almand et al., 2001; Gabrilovich
and Nagaraj, 2009; Rodrı´guez and Ochoa, 2008). Previous
data have shown that a number of proinflammatory medi-
ators are important inducers of these cells, but there has
been no report regarding the involvement of tumor-associ-
ated mitogenic growth factors in the process. Our data link
HGF secreted by MSCs to the expansion of MDSCs. Our
findings can help to explain the strong association of
MDSCs with tumors, since it is well established that in
the tumor microenvironment, HGF is highly secreted by
both the cancer cells themselves and the supporting
stromal cells, promoting cell survival and tumor growth
(Cecchi et al., 2010; Mueller and Fusenig, 2004). While
HGF has been implicated in immunoregulatory responses
(Benkhoucha et al., 2010; Di Nicola et al., 2002), and the
liver, which naturally secretes high levels of HGF, was
reported to have some immunological functions (Sheth
and Bankey, 2001), the specific molecular mechanisms un-
derlying these observations have been largely unexplored
and the reported effects have not been consistently repli-
cated (Le Blanc et al., 2003). Our finding that high numbersFigure 3. MSC Expansion of MDSCs Is Mediated by Secreted HGF
(A) MSC expansion of MDSCs is mediated by secreted factors. Alloge
contact (MSC; three donors) or separated by transwell (TW) and asse
experiments; *p < 0.05 compared with PBL only; n.s., not significant
(B) Highly secreted factors of MSCs (four donors) as assessed by q
stromal-derived factor.
(C and D) Exogenous addition of recombinant HGF to PBLs (five donors
expression of iNOS (top panel) and ARG1 (lower panel) in HGF-expand
using negatively selected CD14 cells that were first gated on FSC/SSC
for either iNOS (top histogram, shaded gray area) or ARG1 expression
control; p = 0.051 for comparison of average number of CD14CD11b+C
compared with 409 ± 46 with HGF treatment); p < 0.05 for ARG1 expres
HGF treatment).
(E) Suppression of anti-CD3/28-stimulated PBL proliferation by HGF
staining for cell division (n = 3; a representative chart is shown).
(F) Knockdown of HGF secretion in MSCs with HGF-specific siRNA abro
cocultured with MSCs (three donors) transfected with either NT siR
compared with MSCs only (leftmost bar) or PBLs only (rightmost bar)
See also Figure S2.
Stem Cof hepatic MDSCs in mice can be significantly altered by
disruption of the HGF/c-Met pathway sheds some mecha-
nistic light on this issue, and, overall, our data demonstrate
that HGF mediates the expansion of functional MDSCs by
engaging c-Met, its receptor, and increasing the phosphor-
ylation of STAT3, one of its downstream molecules.
The immunomodulatory properties of MSCs have been
highlighted as being therapeutic for autoimmune diseases
and other immune-related diseases such as graft-versus-
host disease (Abdi et al., 2008; Djouad et al., 2009; Keating,
2012; Le Blanc et al., 2008). As exciting as these findings
are, some researchers have noted that the same immuno-
modulatory effects of MSCs can allow for the growth of
tumors (Djouad et al., 2003). However, whether MSCs
definitively enhance or inhibit tumor growth and cancer
progression is still unresolved, since differences in the
experimental design, cancer histologic cell type, and MSC
isolation technique used can all affect the experimental
outcome (Klopp et al., 2011; Yen and Yen, 2008).Moreover,
to date, studies on MSC and cancer interactions have
largely focused on the homing of MSCs to tumors, rather
than the immunological aspects of MSCs (Elzaouk et al.,
2006; Studeny et al., 2002; Xin et al., 2007). Although a
considerable amount of data support MSC expansion of
Tregs (Uccelli et al., 2008), and these immunosuppressive
T lymphocytes are also found in tumors, MDSCs appear
to play a more crucial role in maintaining the profound
immune suppression of the tumor niche (Almand et al.,
2001; Ostrand-Rosenberg and Sinha, 2009; Sinha et al.,
2005; Young and Wright, 1992). Our data suggest that
through HGF and the consequent expansion of MDSCs,
MSCs may play a role in maintaining tumor growth.
While the association of MDSCs in a wide range of
cancers has been known for some time, the mechanismsneic PBLs (five donors) were cocultured with MSCs either in direct
ssed for expansion of CD14CD11b+CD33+ MDSCs; five independent
.
uantitative cytokine array. LAP, latency-associated peptide; SDF,
) increases the (C) percentage of MDSCs (*p < 0.05 for trend) and (D)
ed MDSCs (five donors; representative charts shown) as assessed by
(R1), analyzed for CD11b+ and CD33+ (R2), and then further analyzed
(bottom histogram, shaded gray area). Unfilled black line: isotype
D33+ cells (±SEM) expressing iNOS (367 ± 39 without HGF treatment
sion (312 ± 53 without HGF treatment compared with 396 ± 56 with
-expanded MDSCs as assessed by flow-cytometric analysis of CFSE
gates the expansion of MDSCs. Allogeneic PBLs (seven donors) were
NA or siHGF and assessed for CD14CD11b+CD33+ cells. *p < 0.05
; n.s., not significant (NT siRNA compared with siHGF).
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Figure 4. Cancer Cell-Secreted HGF and
In Vivo Manipulation of HGF Expression
in Mice Significantly Alter MDSC Numbers
(A and B) Level of HGF secretion by MSCs,
MG63 (osteosarcoma cell line), human em-
bryonic stem cell-derived mesenchymal
progenitors (EMPs), and JEG-3 (choriocar-
cinoma cell line) (A), and fold expansion of
MDSCs (B) after coculture of the four cell
types with PBLs (three donors; three inde-
pendent experiments; *p < 0.05 for trend).
(C) Knockdown of HGF expression in MSCs
significantly decreases tumor-associated
Gr-1+CD11b+ cells. Tumor growth was
induced in nude mice by inoculating human
colon cancer cells admixed with MSCs
transfected with either control NT siRNA
(n = 5 mice) or siHGF (n = 5 mice). Tumor-
associated leukocytes were assessed for Gr-
1+CD11b+ cells by flow-cytometric analysis
(see Experimental Proceduresfor detailed
description); *p < 0.05, NT siRNA compared
with siHGF.
(D) Gr-1+CD11b+ cells (%) in the spleen and
liver of C57BL/6 (B6) and BALB/c mice (n =
3 mice for each group); *p < 0.05, % of cells
in liver compared with spleen.
(E) Treatment of C57BL/6 mice with the
c-Met inhibitor PHA-665752 (c-Met inh)
significantly decreases hepatic but not
splenic Gr-1+CD11b+F4/80 cells (shown as
a percentage of Gr-1+CD11b+ cells; aver-
age ± SEM; n = 3 mice for each group). *p <
0.05 for c-Met inhibitor treatment versus no
treatment (see Experimental Procedures for
a detailed description).
(F) Tail-vein injection of recombinant HGF
(100 ng) into C57BL/6 mice and assessment
of Gr-1+CD11b+ cells (fold change) in the
peripheral blood, spleen, and bone marrow
1 day and 3 days after injection (n = 6 mice
for each group); *p < 0.05 compared with
day 0.
See also Figure S3.
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are just beginning to be unraveled. IL-6 has been reported
to mediate the expansion of MDSCs, and this cytokine is
known to be secreted by both MSCs and stromal cells
(Hung et al., 2007; Nemunaitis et al., 1989). However, in
this work, we did not find IL-6 to be involved. This may
be due to the lower levels of this cytokine and the masking
of its effects by themuchhigher levels ofHGF in our system
(see Figure 3B). Moreover, the strong association of MDSCs
with cancer suggests that multiple and redundant path-
ways are likely involved (Ostrand-Rosenberg and Sinha,146 Stem Cell Reports j Vol. 1 j 139–151 j August 6, 2013 j ª2013 The Auth2009; Gabrilovich and Nagaraj, 2009). There is consensus,
however, that STAT3 may be the final transcription factor
involved in the expansion of MDSCs. Our finding that
STAT3 activation is involved in HGF-mediated MDSC
expansion further supports the importance of this mole-
cule in inflammation and cancer (Yu et al., 2009).
In summary, we found that HGF secreted by MSCs can
lead to the expansion of MDSCs. MDSCs expanded by
coculture with MSCs or addition of HGF are functional,
expressing iNOS and ARG1, as well as harboring suppres-
sive function and inducing Tregs. Mechanistically, theors
(legend on next page)
Stem Cell Reports j Vol. 1 j 139–151 j August 6, 2013 j ª2013 The Authors 147
Stem Cell Reports
MSC-Secreted HGF Expand MDSCs via c-Met and STAT3
Figure 6. Summary of MSC-Mediated
Expansion of Functional MDSCs
HGF secreted by MSCs binds to its cognate
receptor, c-Met, expressed on CD14 PBLs.
This leads to increased pSTAT3, a critical
transcription factor in MDSC expansion.
Both MSC- and HGF-expanded MDSCs are
functional, expressing ARG1 and iNOS, and
inhibit allogeneic lymphocyte proliferation
while increasing the number of immuno-
modulatory Tregs.
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MSC-Secreted HGF Expand MDSCs via c-Met and STAT3MSC-mediated expansion of MDSCs occurs via the HGF/
c-Met axis, with the downstream involvement of STAT3.
Our findings not only further demonstrate the strong
immunoregulatory nature of MSCs, but also show the
involvement of a mitogenic, noninflammatory molecule
in the expansion of MDSCs.EXPERIMENTAL PROCEDURES
Cell Culture
Human MSCs from bone marrow and placenta were cultured and
expanded as we previously described (Chang et al., 2006; Yen et al.,
2005). Human bone marrowMSCs were purchased from Cambrex
and cultured according to manufacturer’s instructions. For human
placental MSCs, term placentas (38–40 weeks of gestation) fromFigure 5. Expansion of MDSCs by HGF Is Mediated via c-Met, Its R
(A) Expression of c-Met on MDSCs as assessed by flow-cytometric analy
CD11b+ and CD33+ (R2), and then further analyzed for c-Met expression
the flow-cytometric analysis diagrams shown are representative). Rig
0.05 compared with isotype control (Ctrl).
(B) Involvement of c-Met in HGF-mediated expansion of MDSCs. PBLs (
c-Met blocking antibodies (anti-c-Met), treated with recombinant H
cells. PBLs were first gated on FSC/SSC (R1), analyzed for CD14 and
percentages and cell numbers ± SEM are indicated in dot plot diagram
on the right are quantitative summaries of the percentages (top right
*p < 0.05 compared with PBL only or anti-c-Met.
(C) Involvement of STAT3 in HGF-mediated expansion of MDSCs. Reco
leukocytes (eight donors) that were stained for CD11b, CD33, and pSTA
and HGF-treated cells (red unfilled line) were collected for assessmen
isotype control); average cell numbers ± SEM for control (C) and HGF t
right is a quantitative summary of eight independent experiments; *
(D) STAT3 inhibition abrogates HGF-mediated expansion of MDSCs. Re
without addition of cpd188 (STAT3 inhibitor) at the indicated doses
FSC/SSC (R1), analyzed for CD14 and CD11b+ (R2), and then further an
are indicated in dot plot diagrams (1.37% ± 0.22% and 717 ± 108 cells
the percentages (top right) and cell numbers (bottom right) of CD14
compared with PBL only; b, p < 0.05 for trend; n.s., not significant f
See also Figures S4 and S5.
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according to the procedures of the institutional review board.
The cells were isolated as previously described (Yen et al., 2005).
Differentiation studies were carried out as previously described
(Chang et al., 2006; Liu et al., 2011; Yen et al., 2005). Human
PBLs were isolated from the buffy coat of healthy donor blood
samples (Taiwan Blood Services Foundation, Taipei Blood Center,
Taipei, Taiwan) obtained with informed consent according to the
procedures of the institutional review board, and cultured as
previously described (Chang et al., 2006; Liu et al., 2011).
Immunophenotyping
Flow-cytometric analyses of cell surfacemarkers were performed as
previously described (Chang et al., 2006; Liu et al., 2011; Yen et al.,
2005). All antibodies were purchased from BD Biosciences, except
for CD33 and CD11b (BioLegend), ARG1 (R&D Systems), iNOSeceptor, and Increased Phosphorylation of STAT3
sis. PBLs (six donors) were first gated on FSC/SSC (R1), analyzed for
(shaded gray area in histogram; unfilled black line: isotype control;
ht chart: quantification of mean fluorescent intensity (MFI); *p <
six donors) were blocked with isotype control antibodies (IsoAb) or
GF (20 ng/ml), and assessed for expansion of CD14CD11b+CD33+
CD11b+ (R2), and then further analyzed for CD33+ (R3). Average
s (1.54% ± 0.20% and 1,544 ± 201 cells for isotype control). Charts
) and cell numbers (bottom right) of six independent experiments;
mbinant HGF (20 ng/ml) was added to negatively selected CD14
T3. Control cells (no HGF treatment; black unfilled line in histogram)
t by flow cytometry at the indicated time points (shaded gray area:
reatment (H) are indicated below the histograms. The chart on the
p < 0.05 and **p < 0.005.
combinant HGF (20 ng/ml) was added to PBLs (six donors) with and
and assessed by flow cytometry for MDSCs, with PBLs first gated on
alyzed for CD33+ (R3). Average percentages and cell numbers ± SEM
for 5 mM cpd188). Charts on the right are quantitative summaries of
CD11b+CD33+ cells for six independent experiments. a, p < 0.05
or 10 mM cpd188 compared with PBL only.
ors
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MSC-Secreted HGF Expand MDSCs via c-Met and STAT3(Abcam), and c-Met (eBiosciences). All analyses were done on a BD
FACSCalibur flow-cytometric system (BD Biosciences).
Expansion of MDSCs
PBLs were cocultured withMSCs or cancer cell lines (10:1 ratio) for
3 days and then assessed for CD14CD11b+CD33+ cells, which
also served as the cell surface markers for fluorescence-activated
cell sorting (FACS) of MDSCs with the BD Aria Cell Sorter (BD Bio-
sciences). Instead of PBLs, some experiments were performed with
CD14 cells negatively selected with the use of magnetic beads
(Miltenyi Biotec) according to the manufacturer’s instructions.
Transwell studies were performed as previously described using
24-well transwell inserts (0.4 mm pores; BD Falcon) with MSCs
cultured on the culture plates below and PBLs cultured in the
inserts (Liu et al., 2011). Recombinant humanHGF (R&D Systems)
was added to PBLs at the indicated doses.
MDSC Suppression Analysis
Assessment of PBL cell division was performed as previously
described (Chang et al., 2006). Briefly, allogeneic PBLs were labeled
with 2.5 mmol/l of the fluorescent dye carboxyfluorescein succini-
midyl ester (CFSE; Molecular Probes/GIBCO-Invitrogen) for
10 min and then stimulated with anti-CD3/CD28 beads (GIBCO-
Invitrogen). MSC-expandedMDSCswere FACS sorted for homoge-
neity and then cocultured with stimulated allogeneic PBL for
3 days at various effector-to-target (E:T) ratios. Flow-cytometric
analysis was performed to assess for PBL cell division in terms of
CFSE dye intensity.
Quantification of HGF Secretion
Supernatants were collected from cell cultures for detection of HGF
with the use of a commercially available ELISA kit (R&D Systems)
according to the manufacturer’s instructions.
RNAi Experiments
siRNAs specific for IL-6 and HGF were purchased from GIBCO-
Invitrogen, and knockdown experiments were conducted accord-
ing to the manufacturer’s instructions. The efficiency of siRNA
knockdown of MSC-secreted factors was verified by ELISA.
In Vivo Experiments
All animal work was performed in accordance with protocols
approved by the Animal Care and Use Committee of the National
Health Research Institutes. Mice (4–8 weeks old) were obtained
from the National Laboratory Animal Center of Taiwan (Taipei,
Taiwan). Recombinant mouse HGF (100 ng; R&D Systems) was
injected via the tail vein, and C57BL/6 mice were sacrificed
3 days after injection. Peripheral blood, bone marrow, and spleen
were collected for flow-cytometric analysis of Gr-1+CD11b+ cells.
For in vivo tumor studies, nude mice (BALB/c nu/nu) were inocu-
lated subcutaneously with tumor cells (human colon cancer cell
line HCT-116; 1 3 106 cells) admixed with human MSCs (5 3
105 cells at a 1:2 ratio to cancer cells) transfectedwith either control
siRNA (NT siRNA) or HGF-specific siRNA (siHGF). The mice were
sacrificed 3 weeks after inoculation, and tumors were excised and
minced with scissors to obtain leukocytes, which were assessedStem Cfor Gr-1+CD11b+ cells by flow-cytometric analysis. For c-Met
inhibition studies, wild-type C57BL/6 mice were intraperitoneally
injected with vehicle (DMSO, n = 3) or PHA-665752 (Tocris Bio-
science), a c-Met inhibitor (0.15 mg, n = 3) as previously described
(Gordin et al., 2010). Themicewere sacrificed 5 days later and their
livers and spleens were collected for flow-cytometric assessment of
Gr-1+CD11b+ and Gr-1+CD11b+F4/80 cells.
Statistical Analysis
Statistical analysis was performed with SPSS 18.0 software (SPSS),
with statistical significance defined as p < 0.05. Values were
expressed as the mean ± SEM. Student’s t test was used for com-
parisons between two groups, and ANOVA was used for com-
parisons of multiple groups.
For further details regarding the materials and methods used in
this work, see Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and Supplemental
Experimental Procedures and can be found with this article online
at http://dx.doi.org/10.1016/j.stemcr.2013.06.006.
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